SCHEMBL4960760

SCHEMBL4960760

Nc1ccccc1C(=O)NC1CCC(NC(=O)O)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53
GAA P10253 3/20 0.51
CRBN Q96SW2 1/20 0.51
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 3/20 0.50
LMNA P02545 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
HPGD P15428 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
P2RX7 Q99572 1/20 0.50
HTT P42858 1/20 0.50
MAPT P10636 2/20 0.47
SMYD3 Q9H7B4 1/20 0.47
PKM P14618 1/20 0.47
POLB P06746 1/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2060435 0.93 CRBN (0.56) NPC1RAB9AGAACRBNALDH1A1
Water SCHEMBL28110279 0.92 CRBN (0.55) NPC1RAB9AGAACRBNALDH1A1
SCHEMBL28510668 0.87 CRBN (0.51) NPC1RAB9AGAACRBNALDH1A1
SCHEMBL2771765 0.87 CRBN (0.51) NPC1RAB9AGAACRBNALDH1A1
SCHEMBL2771766 0.87 CRBN (0.51) NPC1RAB9AGAACRBNALDH1A1
SCHEMBL22720116 0.87 ALDH1A1 (0.66) NPC1RAB9AGAACRBNALDH1A1
SCHEMBL13161898 0.87 ALDH1A1 (0.61) NPC1RAB9AGAACRBNALDH1A1
SCHEMBL22720137 0.86 RAB9A (0.59) NPC1RAB9AGAACRBNALDH1A1
SCHEMBL13634186 0.86 RAB9A (0.59) NPC1RAB9AGAACRBNALDH1A1
SCHEMBL29229446 0.85 ALDH1A1 (0.69) NPC1RAB9AGAAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008094909-A2 QUINAZOLINONE AND FUSED PYRIMIDINONE COMPOUNDS AND THEIR USE IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-08-07 WO disclosed